Application of COSMO-SAC to Solid Solubility in Pure and Mixed Solvent Mixtures for Organic Pharmacological Compounds

Total Page:16

File Type:pdf, Size:1020Kb

Application of COSMO-SAC to Solid Solubility in Pure and Mixed Solvent Mixtures for Organic Pharmacological Compounds Application of COSMO-SAC to Solid Solubility in Pure and Mixed Solvent Mixtures for Organic Pharmacological Compounds Paul Eric Mullins Thesis submitted to the Faculty of the Virginia Polytechnic Institute and State University in partial fulfillment of the requirements for the degree of Master of Science In Chemical Engineering Dr. Y. A. Liu, Chair Dr. Richey M. Davis Dr. Amadeu K. Sum 24 January 2007 Blacksburg, Virginia Keywords: COSMO, COSMO-SAC, Solubility, Pharmaceutical, Mixed Solvent Application of COSMO-SAC to Solid Solubility in Pure and Mixed Solvent Mixtures for Organic Pharmacological Compounds Paul Eric Mullins Dr. Y. A. Liu, Chair Abstract In this work, we present two open literature databases, the VT-2005 Sigma Profile Database and the VT-2006 Solute Sigma Profile Database, that contain sigma profiles for 1,645 unique compounds. A sigma profile is a molecular-specific distribution of the surface-charge density, which enables the application of solvation-thermodynamic models to predict vapor- liquid and solid-liquid equilibria, and other properties. The VT-2005 Sigma Profile Database generally focuses on solvents and small molecules, while the VT-2006 Solute Sigma Profile Database primarily consists of larger, pharmaceutical-related solutes. We design both of these databases for use with the conductor-like screening model – segment activity coefficient (COSMO-SAC), a liquid-phase activity-coefficient model. The databases contain the necessary information to perform binary and multicomponent VLE and SLE predictions. We offer detailed tutorials and procedures for use with our programs so the reader may also use their own research on our research group website (www.design.che.vt.edu). We validate the VT-2005 Sigma Profile Database by pure component vapor pressure predictions and validate the VT-2006 Solute Sigma Profile Database by solid solubility predictions in pure solvents compared with literature data from multiple sources. Using both databases, we also explore the application of COSMO- SAC to solubility predictions in mixed solvents. This work also studies the effects of conformational isomerism on VLE and SLE property prediction. Finally, we compare COSMO- SAC solubility predictions to solubility predictions by the Non-Random Two-Liquid, Segment Activity Coefficient (NRTL-SAC) model. We find UNIFAC is a more accurate method for predicting VLE behavior than the COSMO-SAC model for many of the systems studied, and that COSMO-SAC predicts solute mole fraction in pure solvents with an average root-mean-squared error (log10(xsol)) of 0.74, excluding outliers, which is greater than the RMS error value of 0.43 using the NRTL-SAC model. Acknowledgments I would like to thank my advisor, Dr. Y. A. Liu, for his support and guidance during my tenure as a student at Virginia Tech. I would also like to thank the members of Dr. Liu’s research group, especially Stephen Fast, Anthony Gaglione, Adel Ghaderi, Bruce Lucas, Richard Oldland, and Kevin Seavey, for being an excellent sounding board for ideas. My parents, Phillip and Joalyn Mullins, and my family deserve special thanks for pushing me to try and be my best in all endeavors in life. I would also like to thank my professional collaborators, Dr. Stanley I. Sandler and his research group at the University of Delaware and Dr. Chau-Chyun Chen, Senior Technology Fellow at Aspen Technology, Inc. Both of these individuals have provided sound advice and guidance backed by many years of experience, and I greatly value their opinions. I would also like to thank our industrial sponsors, Alliant Techsystems, Aspen Technology, Inc., Formosa Petrochemical Co., Honeywell International, Milliken & Co., and SINOPEC Corporation., for providing the funding for the research presented here. Paul Eric Mullins January 24, 2007 Blacksburg, Virginia iii Table of Contents ABSTRACT ................................................................................................................................................................ ii ACKNOWLEDGMENTS......................................................................................................................................... iii TABLE OF CONTENTS ...........................................................................................................................................iv LIST OF FIGURES....................................................................................................................................................vi LIST OF TABLES......................................................................................................................................................ix 1 INTRODUCTION....................................................................................................................................................1 1.1 BACKGROUND AND SIGNIFICANCE OF THIS RESEARCH ...............................................................................1 1.2 OBJECTIVES OF THIS RESEARCH..................................................................................................................2 2 THEORY ..................................................................................................................................................................4 2.1 OVERVIEW OF COSMO-SAC MODEL.........................................................................................................4 2.1.1 Derivation of Segment Activity-Coefficient Model ................................................................................5 2.1.2 Sigma Profiles........................................................................................................................................8 2.2 OVERVIEW OF DENSITY-FUNCTIONAL THEORY ........................................................................................11 2.3 SOLUBILITY THEORY.................................................................................................................................12 2.3.1 Overview of Solubility..........................................................................................................................12 2.3.2 Derivation of Solubility Equation from Solid-Liquid Equilibrium.......................................................12 2.4 ESTIMATION METHODS FOR MELTING TEMPERATURE AND HEATS OF FUSION .........................................15 2.4.1 Estimation of Normal Melting-Point Temperature..............................................................................15 2.4.2 Estimation of Latent Heat of Fusion....................................................................................................16 2.5 OVERVIEW OF NRTL-SAC THEORY .........................................................................................................18 3 COMPUTATIONAL METHODS AND VALUES .............................................................................................20 3.1 PROCEDURE FOR GENERATING SIGMA PROFILES ......................................................................................20 3.1.1 Ideal Gas-Phase Geometry Optimization ............................................................................................21 3.1.2 Condensed Phase Energy Calculation.................................................................................................22 3.1.3 COSMO Calculation – Surface Segment Averaging............................................................................23 3.2 GEOMETRY OPTIMIZATION TOOLS ............................................................................................................24 3.2.1 Amber8.................................................................................................................................................24 3.2.2 MS Forcite Plus Annealing Dynamics.................................................................................................25 3.2.3 Qualitative Comparison of Methods....................................................................................................26 3.3 CONVERGENCE METHOD FOR SOLUBILITY PREDICTIONS..........................................................................28 4 VT-2005 SIGMA PROFILE DATABASE...........................................................................................................29 4.1 DESCRIPTION OF DATABASE......................................................................................................................29 4.2 VALIDATION OF VT-2005 SIGMA PROFILE DATABASE..............................................................................33 4.2.1 Pure Component Vapor-Pressure Predictions.....................................................................................34 4.2.2 Activity-Coefficient Predictions...........................................................................................................35 4.3 DETAILS OF VT-2005 SIGMA PROFILE DATABASE RELEASE AND REFINEMENT........................................35 4.4 EFFECT OF CONFORMATIONAL ISOMERISM ON THERMODYNAMIC PROPERTY PREDICTION ......................36 4.4.1 Small Molecule Example: 2-Methoxy-ethanol....................................................................................38 4.4.2 Medium-Sized Molecule Example: Benzyl Benzoate ..........................................................................47 4.5 CONFORMATIONAL IMPROVEMENTS OF SELECT RELEASED COMPOUNDS .................................................52 4.5.1 Polar Solvent: Ethanol.........................................................................................................................53
Recommended publications
  • Urinary Paraben Concentrations and Ovarian Aging Among Women from a Fertility Center
    Urinary Paraben Concentrations and Ovarian Aging among Women from a Fertility Center The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Smith, Kristen W., Irene Souter, Irene Dimitriadis, Shelley Ehrlich, Paige L. Williams, Antonia M. Calafat, and Russ Hauser. 2013. “Urinary Paraben Concentrations and Ovarian Aging among Women from a Fertility Center.” Environmental Health Perspectives 121 (11-12): 1299-1305. doi:10.1289/ehp.1205350. http://dx.doi.org/10.1289/ehp.1205350. Published Version doi:10.1289/ehp.1205350 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:11879222 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA All EHP content is accessible to individuals with disabilities. A fully accessible (Section 508–compliant) HTML version of this article is available at http://dx.doi.org/10.1289/ehp.1205350. Research Urinary Paraben Concentrations and Ovarian Aging among Women from a Fertility Center Kristen W. Smith,1 Irene Souter,2 Irene Dimitriadis,1,2 Shelley Ehrlich,1 Paige L. Williams,3 Antonia M. Calafat,4 and Russ Hauser1,2 1Department of Environmental Health, Harvard School of Public Health, Boston, Massachusetts, USA; 2Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, Harvard Medical School/Massachusetts General Hospital Fertility Center, Boston, Massachusetts, USA; 3Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts, USA; 4National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA In 2008, the Cosmetic Ingredient Review BACKGROUND: Parabens are preservatives commonly used in personal care products, pharmaceuticals, Panel concluded that parabens used in cos- and foods.
    [Show full text]
  • Studies on the Effects of Paraben Mixtures on MCF-7 Breast Cancer
    Studies on the Effects of Paraben Mixtures on MCF-7 Breast Cancer Cells in Culture A thesis submitted in partial fulfilment of the requirements for the Degree of Masters of Science in Biochemistry In the Department of Chemistry At the University of Canterbury New Zealand By Kristie Webber University of Canterbury 2013 Table of Contents Acknowledgements .............................................................................................................................. i Abstract ............................................................................................................................................... ii Abbreviations ..................................................................................................................................... iii List of figures and tables .................................................................................................................... iv 1 Introduction ......................................................................................................................................... 1 1.1 Hormones and the endocrine system ........................................................................................... 2 1.2 Estrogens ....................................................................................................................................... 5 1.2.1 What are estrogens? .............................................................................................................. 5 1.2.2 17β-Estradiol .........................................................................................................................
    [Show full text]
  • Science of the Total Environment 445–446 (2013) 299–305
    Science of the Total Environment 445–446 (2013) 299–305 Contents lists available at SciVerse ScienceDirect Science of the Total Environment journal homepage: www.elsevier.com/locate/scitotenv Relationship between urinary triclosan and paraben concentrations and serum thyroid measures in NHANES 2007–2008 Erika S. Koeppe, Kelly K. Ferguson, Justin A. Colacino, John D. Meeker ⁎ Department of Environmental Health Sciences, University of Michigan School of Public Health, Ann Arbor, MI, United States HIGHLIGHTS ► Triclosan and parabens are widely used in the US and elsewhere. ► Biomarkers of exposure were examined in relation to serum thyroid hormone levels. ► In adults, we observed inverse associations between parabens and thyroid hormones. ► In adolescents, we observed positive associations between triclosan and total T3. ► Future research is necessary to confirm findings and explore clinical relevance. article info abstract Article history: Triclosan and parabens are broad spectrum antimicrobials used in a range of consumer products. In vitro and Received 28 September 2012 animal studies have suggested the potential for these compounds to disrupt thyroid function, though studies Received in revised form 17 December 2012 in humans have been limited. The objective of the study was to assess the relationship of urinary concentra- Accepted 17 December 2012 tions of triclosan and parabens with serum thyroid measures in a large, representative sample of the US pop- Available online 20 January 2013 ulation. We conducted an exploratory, cross-sectional analysis of data on urinary biomarkers of triclosan and paraben exposure and serum thyroid measures obtained from 1831 subjects (ages≥12 years) as part of the Keywords: – Biomarkers 2007 2008 National Health and Nutrition Examination Survey (NHANES).
    [Show full text]
  • Part I Biopharmaceuticals
    1 Part I Biopharmaceuticals Translational Medicine: Molecular Pharmacology and Drug Discovery First Edition. Edited by Robert A. Meyers. © 2018 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2018 by Wiley-VCH Verlag GmbH & Co. KGaA. 3 1 Analogs and Antagonists of Male Sex Hormones Robert W. Brueggemeier The Ohio State University, Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Columbus, Ohio 43210, USA 1Introduction6 2 Historical 6 3 Endogenous Male Sex Hormones 7 3.1 Occurrence and Physiological Roles 7 3.2 Biosynthesis 8 3.3 Absorption and Distribution 12 3.4 Metabolism 13 3.4.1 Reductive Metabolism 14 3.4.2 Oxidative Metabolism 17 3.5 Mechanism of Action 19 4 Synthetic Androgens 24 4.1 Current Drugs on the Market 24 4.2 Therapeutic Uses and Bioassays 25 4.3 Structure–Activity Relationships for Steroidal Androgens 26 4.3.1 Early Modifications 26 4.3.2 Methylated Derivatives 26 4.3.3 Ester Derivatives 27 4.3.4 Halo Derivatives 27 4.3.5 Other Androgen Derivatives 28 4.3.6 Summary of Structure–Activity Relationships of Steroidal Androgens 28 4.4 Nonsteroidal Androgens, Selective Androgen Receptor Modulators (SARMs) 30 4.5 Absorption, Distribution, and Metabolism 31 4.6 Toxicities 32 Translational Medicine: Molecular Pharmacology and Drug Discovery First Edition. Edited by Robert A. Meyers. © 2018 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2018 by Wiley-VCH Verlag GmbH & Co. KGaA. 4 Analogs and Antagonists of Male Sex Hormones 5 Anabolic Agents 32 5.1 Current Drugs on the Market 32 5.2 Therapeutic Uses and Bioassays
    [Show full text]
  • Paraben and Breast Cancer: a Stromal Link
    University of Tennessee, Knoxville TRACE: Tennessee Research and Creative Exchange Doctoral Dissertations Graduate School 5-2020 Paraben and Breast Cancer: A Stromal Link Emily Hager University of Tennessee, [email protected] Follow this and additional works at: https://trace.tennessee.edu/utk_graddiss Recommended Citation Hager, Emily, "Paraben and Breast Cancer: A Stromal Link. " PhD diss., University of Tennessee, 2020. https://trace.tennessee.edu/utk_graddiss/5915 This Dissertation is brought to you for free and open access by the Graduate School at TRACE: Tennessee Research and Creative Exchange. It has been accepted for inclusion in Doctoral Dissertations by an authorized administrator of TRACE: Tennessee Research and Creative Exchange. For more information, please contact [email protected]. To the Graduate Council: I am submitting herewith a dissertation written by Emily Hager entitled "Paraben and Breast Cancer: A Stromal Link." I have examined the final electronic copy of this dissertation for form and content and recommend that it be accepted in partial fulfillment of the equirr ements for the degree of Doctor of Philosophy, with a major in Nutritional Sciences. Ling Zhao, Major Professor We have read this dissertation and recommend its acceptance: Jay Whelan, Guoxen Chen, Hwa-Chain Wang Accepted for the Council: Dixie L. Thompson Vice Provost and Dean of the Graduate School (Original signatures are on file with official studentecor r ds.) Paraben and Breast Cancer: A Stromal Link A Dissertation Presented for the Doctor of Philosophy Degree The University of Tennessee, Knoxville Emily Nicole Hager May 2020 ACKNOWLEDGMENTS I am greatly honored and humbled to have pursued my Ph.D.
    [Show full text]
  • A10 Anabolic Steroids Hardcore Info
    CONTENTS GENERAL INFORMATION 3 Anabolic steroids – What are they? 4 How do they Work? – Aromatisation 5 More molecules – More problems 6 The side effects of anabolic steroids 7 Women and anabolic steroids 8 Injecting steroids 9 Abscesses – Needle Exchanges 10 Intramuscular injection 11 Injection sites 12 Oral steroids – Cycles – Stacking 13 Diet 14 Where do steroids come from? Spotting a counterfeit 15 Drug Information – Drug dosage STEROIDS 16 Anadrol – Andriol 17 Anavar – Deca-Durabolin 18 Dynabolon – Durabolin – Dianabol 19 Esiclene – Equipoise 20 Primobolan Depot – Proviron – Primobolan orals – Pronobol 21 Sustanon – Stromba, Strombaject – Testosterone Cypionate Testosterone Enanthate 22 Testosterone Propionate – Testosterone Suspension 23 Trenbolone Acetate – Winstrol OTHER DRUGS 24 Aldactone – Arimidex 25 Clenbuterol – Cytomel 26 Ephedrine Hydrochloride – GHB 27 Growth Hormone 28 Insulin 30 Insulin-Like Growth Factor-1 – Human Chorionic Gonadotrophin 31 Tamoxifen – Nubain – Recreational Drugs 32 Steroids and the Law 34 Glossary ANABOLIC STEROIDS People use anabolic steroids for various reasons, some use them to build muscle for their job, others just want to look good and some use them to help them in sport or body building. Whatever the reason, care needs to be taken so that as little harm is done to the body as possible because despite having muscle building effects they also have serious side effects especially when used incorrectly. WHAT ARE THEY? Anabolic steroids are man made versions of the hormone testosterone. Testosterone is the chemical in men responsible for facial hair, deepening of the voice and sex organ development, basically the masculine things Steroids are in a man. used in medicine to treat anaemia, muscle weakness after These masculine effects surgery etc, vascular are called the androgenic disorders and effects of testosterone.
    [Show full text]
  • Miss.Julie ^ ^ Email:[email protected] Skype:[email protected] Whatsapp:+8618872220730
    Miss.Julie ^ _ ^ Email:[email protected] Skype:[email protected] Whatsapp:+8618872220730 Raw anabolic steroid hormone powders from China with high purity&safe delivery Powder list : Testosterone enanthate Testosterone cypionate Testosterone propionate Testosterone-Sustanon250 Testosterone phenylpropionate Testosterone Acetate Testosterone decanoate Testosterone-Base Testosterone Isocaproate Testosterone undecanoate 17a-Methyl-1-Testosterone Fluoxymesterone(Halotesin) Mesterolone(Proviron) Methyltestosterone Trenbolone Acetate Trenbolone enanthate Trenbolone Base Metribolone Trenbolone Hexahydrobenzyl Carbonate Nandrolone decanoate Nandrolone Propionate Nandrolone phenylpropionate Nandrolone Mestanolone Drostanolone enanthate Drostanolone propionate (Masteron) 17a-Methyl-Drostanolone (Methasterone) Boldenone undecylenate (EQ) Methenolone Acetate Methenolone Enanthate (primobolin) Boldenoe cypionate Boldenoe Acetate Methandrostenolone (Dianabol) Oxandrolone (Anavar) Oxymetholone (Anadrol) Stanozolol (Winstrol) Turinabol Clostebol Acetate Anastrozloe (Arimidex) Clomiphene Citrate(Clomid) Exemestane Letrozole (Femara) Mifepristone Tamoxifen Citrate Semi-finished Injectable / Oral steroids: Test prop-----------100mg/ml 200mg/ml Test enan-----------250mg/ml 300mg/ml 400mg/ml 500mg/ml 600mg/ml Test cyp------------200mg/ml 250mg/ml 300mg/ml Test Sustanon-------200mg/ml 250mg/ml 300mg/ml 400mg/ml Deca----------------200mg/ml 250mg/ml Equipoise-----------200mg/ml 300mg/ml Tren ace------------100mg/ml 200mg/ml Tren enan-----------100mg/ml
    [Show full text]
  • MMC International BV
    M.M.C. International Steroid Substances Steroid Test A Colour Steroid Test B Colour Steroid Test B Colour with UV Light Stanozolol/ Oxandrolone Test Clenbuterol/ Oxymetholone Test Ephedrine Test Alfadolone Orange Yellow Nil - - - Androsterone Orange Yellow White - - - Beclometasone Brown–yellow Orange Nil - - - Betamethasone Orange–brown Pink–Orange Nil - - - Boldenone Base (Equipoise, Ganabol) (pure powder) Warm red after 2 min. Dark Orange after 2 min. Bright Light Orange - - - Boldenone Undecanoate (oil) Dark brownish-red Dark Red Bright Light Orange - - - Boldenone Undecylenate (oil) Orange - Light Brown Dark Orange → Brown Bright Light Orange-Yellow - - - Carbenoxolone (CBX) Orange Yellow Yellow - - - Cholesterol Violet Orange White - - - Clenbuterol (Spiropent, Ventipulmin) - - - - Purple - Dark brown with yellow-green on the Dark brown with yellow-green on the Clomiphene (Androxal, Clomid, Omifin) Nil Dark brown to black No reaction Dark brown to black sides of the ampoule sides of the ampoule Cortisone Orange Yellow Green - - - Desoxycortone Blue–black Yellow Yellow - - - Dexamethasone Yellow Orange–pink Nil - - - Dienestrol Yellow Orange–red Nil - - - Diethylstilbestrol (DES) Orange (→yellow–green) Nil - - - Dimethisterone Brown–green Orange–red Yellow - - - Drostanolone Propionate (Masteron) (oil) Bright green Yellow-Orange Orange - - - Dydrogesterone (Duphaston) - Orange Green-Yellow - - - Enoxolone Orange Yellow Green-Yellow - - - Ephedrine (also for Pseudo- and Nor-Ephedrine) - - - - - Orange Estradiol (Oestradiol) Orange
    [Show full text]
  • 206679Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 206679Orig1s000 PHARMACOLOGY REVIEW(S) DEPARTMENT OF HEALTH AND HUMAN SERVICES PUBLIC HEALTH SERVICE FOOD AND DRUG ADMINISTRATION CENTER FOR DRUG EVALUATION AND RESEARCH PHARMACOLOGY/TOXICOLOGY NDA/BLA REVIEW AND EVALUATION Application number: 206679 Supporting document/s: SDN10, SN0000 Applicant’s letter date: June 22, 2015 CDER stamp date: June 22, 2015 Product: Simvastatin oral suspension Indication: Treatment of primary and homozygous familial hypercholesterolemia in adults and for the treatment of heterozygous familial hypercholesterolemia in adult and pediatric patients (≥10 years) Applicant: Rosemont Pharmaceuticals (a wholly owned subsidiary of Perrigo Pharmaceuticals, U.S. agent) Review Division: Division of Metabolism and Endocrinology Products Reviewer/Team Leader: C. Lee Elmore, PhD Division Director: Jean-Marc Guettier, MD Project Manager: Richard Whitehead Disclaimer Except as specifically identified, all data and information discussed below and necessary for approval of NDA 206679 are owned by Rosemont Pharmaceuticals Ltd. or are data for which Rosemont Pharmaceuticals Ltd. has obtained a written right of reference. Any information or data necessary for approval of NDA 206679 that Rosemont Pharmaceuticals Ltd. does not own or have a written right to reference constitutes one of the following: (1) published literature, or (2) a prior FDA finding of safety or effectiveness for a listed drug, as reflected in the drug’s approved labeling. Any data or information described or referenced below from reviews or publicly available summaries of a previously approved application is for descriptive purposes only and is not relied upon for approval of NDA number 206679. 1 Reference ID: 3906236 NDA 206679 Reviewer/Team Leader: C.
    [Show full text]
  • Methyl and Propyl Parabens Screening Profile Parabens Are Contaminants That Have Been Found in Potential Drinking Water Sources in Minnesota
    CONTAMINANTS OF EMERGING CONCERN PROGRAM Methyl and Propyl Parabens Screening Profile Parabens are contaminants that have been found in potential drinking water sources in Minnesota. The information in this profile was collected for the screening process of the Minnesota Department of Health’s Contaminants of Emerging Concern (CEC) program. The chemicals nominated to the CEC program are screened and ranked based on their toxicity and presence in Minnesota waters. Based on these rankings, some chemicals are selected for a full review. CEC program staff have not selected methyl or propyl paraben for full reviews. Methyl and Propyl Parabens Uses Potential Health Effects Parabens are antimicrobial chemicals used as Parabens are potential endocrine (hormone) preservatives in packaged foods, pharmaceuticals, disruptors, but their estrogen activity is much lower cosmetics, and personal care products. Methyl and than natural estradiol.4 Parabens have been detected propyl parabens are commonly found together in in human breast cancer tissue; however, studies have paraben mixtures used in consumer products. not shown that parabens actually cause breast cancer.4 Much of what is known about endocrine disruption is Parabens in the Environment based on limited studies, which in some cases have Based on a study Minnesota Pollution Control Agency produced conflicting results. These studies may not (MPCA) did in Minnesota in 2010, parabens are represent what might happen when humans ingest widespread in Minnesota’s surface water. Twenty-one methyl or propyl parabens from food or water.4 percent of streams sampled had propyl paraben, with a maximum concentration of 0.6 parts per billion Based on the screening assessment, it is unclear (ppb).
    [Show full text]
  • United States Patent (10) Patent No.: US 7,790,910 B2 Macdonald Et Al
    US007790910B2 (12) United States Patent (10) Patent No.: US 7,790,910 B2 MacDonald et al. (45) Date of Patent: Sep. 7, 2010 (54) PROCESS FOR THE PREPARATION OF 2003/0069434 A1 4/2003 Bohlmann et al. 7OALKYLATED 19-NORSTEROIDS 2005, OO33085 A1 2/2005 Warren et al. (75) Inventors: Peter Lindsay MacDonald, Gentilino FOREIGN PATENT DOCUMENTS (CH); Ettore Bigatti, Balerna (CH): DE 24, 29 O40 1, 1975 Pierluigi Rossetto, Balerna (CH) DE 19622 457 11, 1997 EP O138504 T 1988 (73) Assignee: Sicor Inc., Irvine, CA (US) WO WO93/10741 6, 1993 WO WO99/33855 * 7/1999 (*) Notice: Subject to any disclaimer, the term of this WO WO99,42109 8, 1999 patent is extended or adjusted under 35 WO WOO2,32922 4/2002 U.S.C. 154(b) by 1427 days. WO WOO3,O31399 4/2003 WO WOO3,O45972 6, 2003 (21) Appl. No.: 11/192,071 WO WO98,07740 T 2003 (22) Filed: Jul. 27, 2005 OTHER PUBLICATIONS Bucourt, et al., “New Biospecific Adsorbents For The Purification Of (65) Prior Publication Data Estradiol Receptor'. Journal of Biological Chemistry, 1978, pp. 8221-8228, vol. 253, No. 22. US 2006/OO30552 A1 Feb. 9, 2006 Dasilva, et al., “Synthesis And Structure-Affinity Of A Series of 7alpha-Undecylestradiol Derivatives: A Potential Vector For Related U.S. Application Data Therapy And Imaging Of Estrogen-Receptor-Positive Cancers'. Journal of Medicinal Chemistry, 1990, pp. 430-434, vol. 33, No. 1. (60) sy, priat e.sfas: A.i Skaddan, et al., “Synthesis And Binding Affinities Of Novel Re s proV1S1ona application o, o s , Ille Containing 7.Alpha.-Substituted Estradiol Complexes: Models For on Aug.
    [Show full text]
  • Interactions of Nandrolone and Psychostimulant Drugs on Central Monoaminergic Systems. National Institute for Health and Welfare (THL), Research 30
    Sanna Kailanto Sanna Kailanto Interactions of Nandrolone Sanna Kailanto and Psychostimulant Drugs RESEARCH Interactions of Nandrolone and RESEARCH Psychostimulant Drugs on Central on Central Monoaminergic Monoaminergic Systems Systems Monoaminergic Systems Monoaminergic Central on Drugs Psychostimulant and Nandrolone of Interactions This study had four main aims. First, it aimed to explore the effects of nandrolone decanoate on dopaminergic and serotonergic activities in rat brains. Second, it set out to assess whether nandrolone pre-exposure modulates the acute neurochemical and behavioral effects of psychostimulant drugs in experimental animals. A third aim was to investigate if AAS-pretreatment-induced changes in brain reward circuitry are reversible. Finally, the study was also intended to evaluate the role of androgen receptors in nandrolone’s ability to modulate the dopaminergic and serotonergic effects of stimulants. The results of the study show that AAS pretreatment inhibits the reward- related neurochemical and behavioral effects of amphetamine, MDMA and cocaine in experimental animals. Given that LMA, stereotyped behavior and accumbal outflow of DA and 5-HT are all related to reward, this study suggests that nandrolone, at tested doses, significantly affects the rewarding properties of stimulant drugs. Furthermore, it seems that these effects could be long- lasting and that the ability of nandrolone to modulate reward-related effects of stimulants depends on AR or ER activation. .!7BC5<2"HIFILD! National Institute for Health and Welfare P.O. Box 30 (Mannerheimintie 166) FI-00271 Helsinki, Finland Telephone: +358 20 610 6000 30 ISBN 978-952-245-258-0 www.thl.fi 30 2010 30 Sanna Kailanto Interactions of Nandrolone and Psychostimulant Drugs on Central Monoaminergic Systems Academic dissertAtIoN To be presented with the permission of the Faculty of Biological and Environmental Sciences, University of Helsinki, for public examination in the Arppeanum auditorium, Helsinki University Museum, Snellmaninkatu 3, Helsinki, on April 29nd, at 12 o’clock noon.
    [Show full text]